|
|
Support : eNewsletters
: Eye on Innovation : Issue 2, December 2009

When is hot hot—Innovation in the medical devices market
Although innovation can occur anywhere in the organization, many companies
view it as synonymous with new product development or traditional R&D.
But such a shortsighted view can lead to the erosion of competitive advantage.
Use Dialog to track innovation in your industry and inspire it within your
organization, from identifying new players to spying out global market opportunities.
This issue of Eye on Innovation explores innovation in the medical devices
market, a major part of the multifaceted healthcare industry. We will look
for clues to see who's innovating in the area of cardiovascular medical devices
in the United States and investigate whether China may become a player in the
medical devices market.
And, oh yes, we want to follow up by answering questions we posed on solar
energy innovation in Eye on Innovation, Issue 1
Get an early warning: Mine Dialog for medical devices trademarks
Keeping an eye on the competition's trademarks can tell you a great deal
about the quality of a firm's incremental innovations. If each improvement
is given its own new mark, trademarks also can be used to chart the course
of product differentiation. Recent advances in international filing and registration
of marks has increased the potential use of trademark statistics as a source
of information for industrial and innovation studies. Observing trademarks
allows you to make inferences about companies' behavior on branding strategies,
introductions of new goods and services and upgrade or repositioning of old
products
Medical devices: Promising strides
Innovative methods are continually being developed for diagnosing and treating
various health conditions particularly in the medical devices market. Medical
devices include a wide range of products varying in complexity and application
from simple tongue depressors and medical thermometers to meters that measure
oxygen levels to complex x-ray machines. The demand for safe and reliable medical
devices is growing among both clinicians and consumers.
Three major medical device equipment segments—cardiovascular, orthopedic and
neurological—constitute about two-thirds of the market's revenues and are the
fastest-growing sectors of the market. We'll zero in on cardiovascular devices.

Medical devices for heart disease
Poor nutritional habits and unhealthy lifestyles are contributing to an increase
in cardiovascular diseases in the developed and developing world. Cardiovascular
medical products, such as pacemakers, coronary stents, implantable cardiac
defibrillators and angioplasty products dominate the world scene. For these,
the United States market, estimated at more than $100 billion, is driving
the most notable innovations and developments.
News reports and an industry outlook suggest the industry continues to be
one of the fastest growing industries within the healthcare sector throughout
the world. Will steady growth in the cardiovascular medical devices market
continue in the future? What can you expect and who are the major players with
whom you might have to compete?
Be methodical: Check the Dialog tea leaves before making your move
Trademark filing data can offer clues about what your competition is up to
and illustrate new marketing trends. Innovating firms make extensive use
of trademarks. For example, IBM lists more than 1,200 trademarks on its home
page. We'll conduct several searches in Dialog's global trademark collection
to investigate the medical devices market.
Step 1: Identify activity by the top players.
Just who is actively filing trademarks for future cardiovascular medical devices?
Searching TRADEMARKSCAN® – U. S. Federal on Dialog for trademarks in the
medical devices field locates a list of companies actively filing “intent
to use” trademarks for future cardiovascular medical devices like stents,
pacemakers, defibrillators and more. For the last five years, we identify
the top companies filing trademarks for cardiovascular-related medical devices.
Medtronic leads the list with Pacesetter and Biotronik following closely
behind. If we compare the five-year results with a search of just the last
year, we see that Medtronic has been a steady industry leader in trademark
filing for five years; however, Biotronik has filed 10 “intent to use” trademarks
in this market in just the past year. Although Medtronic and Pacesetter have
only filed four each, they still continue their presence. While not at the
top of the first wave, Biotronik is showing increased interest in this field.
Dark horses are Invatec Technology Center and Abbott Cardiovascular Systems,
who both filed five marks this year.
Step 2: Know your competition: who wins and who loses?
Now that you have a list of companies that appear interested in cardiovascular medical devices, Dialog offers more. Search your competitor's business name using Dialog's comprehensive collection of business and industry trade journals, newswires, newspapers and newsletters, Dun & Bradstreet comprehensive reports and market research from Investext. Looking at a company's assets/liabilities, news press, credit and risk reports, the industry outlook and more will help you predict whether these companies may actually use their medical devices trademarks in the future.
Our business review suggests companies at the top of our trademark list show
strength in this market. Although Medtronic, a leader in the medical devices
industry, has suffered from restructuring charges, an unfavorable patent litigation
settlement and lost market share, the company still continues high sales in
the cardiovascular sector and has received a new U.S. patent related to unique
electrodes and/or electrical lead assemblies for stimulating cardiac tissue.
Biotronik, a pioneer in the field of telecardiology, was nominated for the
most important award for achievements and innovation in Germany. Not only did
Biotronik identify the potential of telecardiology early, but also pioneered
its successful implementation in the market. Because of increased demand for
its innovative product, it is currently expanding its business. And, Edwards
Life Sciences and Cameron Health received approval for their devices allowing
for commercialization of their products in the European Union and countries
in Asia and Latin America. Abbott Cardiovascular has the potential to enter
this market. The company had higher than expected earnings; an acquisition
to support its position in the cardiovascular market; a favorable patent litigation
settlement and approval in China for a next-generation drug-eluting stent.
Step 3: Expand your search worldwide. China: opportunity or threat?
What does
a company need to do to succeed today? Find the opportunity. Look below the
radar at China, the wild, wild east of medical devices. Let's see what the
trademark crystal ball tells us. Results from our search indicate Chinese trademarks
are increasing. Non-Chinese medical devices companies active in China are also
major players in the industry worldwide and include Johnson & Johnson,
Medtronics, Edwards LifeSciences, to name a few. The Chinese company Zhe Jiang
Hao Zhong Hao Jian Kang Chan Pin You has exploded into the medical devices
market with 83 trademarks in this year alone, while Ha Er Bin Le Tai Yao Ye
You Xian Gong Si continues its presence with 20 new trademarks in 2009 for
a total of 100 in the last five years. An interesting note is the Chinese company
Guang Zhou Da Ming Lian He Xiang Jiao Zhi Pin, a holder of 85 trademarks for
the last five years, filed no new trademarks in 2009—has the company changed
directions?
The medical devices industry in China is young, but maturing rapidly, and has
been growing steadily as a result of more interest from local medical facilities
in importing foreign devices. From 2001 through 2008, Chinese imports of medical
devices increased dramatically; however; local manufacturers still account
for the majority of sales. Moreover, foreign companies continue to partner
with Chinese firms to gain access to the world's fastest-growing devices market.
Demand can only increase as the population ages, digital and biomedical technologies
continue to advance, and an ever larger number of people have the resources
to become customers. Cardiovascular product sales are projected to increase
attesting to the significant opportunity in China.
Conclusions and Next Steps—Are you better at spotting the forest or the trees?
Tracking trademarks allows us to make inferences about companies' behavior
in terms of branding strategies, introductions of new goods and services
and upgrade or repositioning of old products. With just a few short searches
on Dialog, we now understand how we can learn about medical device technologies
rapidly making their way toward the market and what competing technologies
may become available and from whom. By knowing what research is being conducted
and where and how far the technology is from the market, we learn how upcoming
research is likely to affect current products and technologies.
As a result of the trademark and company searches, you can explore further:
- Check the Goods & Services trademark descriptions. You may pick up
hints on types of cardiovascular and other medical devices—is a device
a spin-off of a pre-existing product or something new and different that
your company hasn't considered, for example, implantable and wireless medical
devices.
- Find out which countries are expanding into the market.
- Watch for the next generation of cardiovascular devices.
- Track the trademark filings over time to follow product variations that
seem to be gaining in popularity.
The rationale for believing that past successes will continue into the near
future is compelling but far from guaranteed. You now have actionable intelligence
to influence your development of new products, conduct further investigations,
determine mergers and acquisitions to pursue for a more competitive position
and decide the place your company can expect to have in the future of this
important market in the healthcare revolution. When the economy turns around,
those companies that have found ways to maintain their pace of innovation will
be positioned to capture market share and succeed in the long run. Don't be
late to the party; partner with Dialog on innovation in this hot market.
Don't miss the next issue!
Sign up now
Dialog has more ideas to share to help you become innovative in the marketplace.
Each issue of Eye on Innovation will illustrate ways you can use Dialog content
and search tools to gather your own intelligence, expand your knowledge of
potential product niches and show you who's doing what in your market—in essence,
how you can turn information into actionable intelligence! Subscribe
now to
view upcoming topics that will give you a leg up on your competition's strengths
and weaknesses and identify opportunities for and threats to your own business.
|
From Issue 1: Solar energy update
With one or more Dialog Alerts, we continued to monitor the progress of companies we researched in Eye on Innovation, Issue 1. New funding sources and partnerships often enhance a company's position and allow for innovation in the marketplace; on the contrary, management changes, loss of dollars and dissolution of joint ventures suggest trouble ahead. Here are some recent headlines about companies we researched in our last issue that suggest both.
Heading the list of positive results
At the top of our list of innovative solar energy companies this month is Noveda Technologies, mentioned positively several times.
- "Noveda Technologies Awarded Funding Under New Jersey's Clean Energy Manufacturing Fund." New funding may give Noveda the impetus to increase its position in the solar energy market. Noveda suggests "expansion from its current staff of 17 to 100 by 2013," another telltale sign of success in the market.
- "Noveda is the recipient of the Market Innovator Award from the New Jersey Clean Energy Program and is on track to earn its third consecutive 100-point Energy Star Performance Award."
- "Noveda Technologies announces a strategic partnership with EnergyWatch to help promote energy efficiency technologies and services for large businesses.
- "GreenVolts' innovative approach to concentrating photovoltaics has led to a power purchase agreement with Pacific Gas & Electric for a two-megawatt pilot facility in Northern California. GreenVolts has raised nearly $45 Million in venture capital, including $34 million as part of a Series B round late last year. The company is also working with the National Renewable Energy Laboratory to optimize solar cells for concentrating photovoltaic systems."
- KYOCERA Solar Modules Exceed Performance Expectations."
Outside the United States
G24 Innovations (G24i), a global pioneer of dye-sensitized solar cells, announced the commercial shipment of DSSC photovoltaic modules to Hong Kong, making it the first commercial manufacturer of DSSC technology for mass-consumer use in the world. G24 indicates this venture is the first of a number of commercial partnerships under active development.
Other not so positive news
One of the companies mentioned in Issue 1 is selling out; another is having funding problems and changing its management and a third's joint venture is in jeopardy. On these companies we'll have to wait and see.
- "Allora Minerals signs binding Letter of Intent to purchase OptiSolar manufacturing facilities, production lines, intellectual property and R&D facility and related assets."
- "DayStar Technologies announces termination of letter of intent with EPOD Solar Inc. and board of directors and management changes."
- Sempra Energy issued the following statement: "RBS may have to divest its interest in the RBS Sempra Commodities joint venture." This revelation may threaten Sempra Energy's funding abilities.
CEOs rank innovation
Faced with slow growth and global competition, many CEOs view innovation as critical to corporate success. For example, William Ford Jr., chairman and CEO of Ford Motor Co., made the point that, "innovation will be the compass by which the company sets its direction" and that Ford "will adopt innovation as its core business strategy going forward." Echoing those comments, Jeffrey Immelt, chairman and CEO of General Electric Co., has talked about the "innovation imperative," a belief that innovation is central to the success of a company and the only reason to invest in its future. GE is pursuing some 100 "imagination breakthrough" projects to drive growth through innovation. And, Steve Ballmer, Microsoft's CEO, stated that "innovation is the only way that Microsoft can keep customers happy and competitors at bay."
In the next issue...
In Issue 3 we'll explore scientific literature using specific Dialog techniques.
Don't miss this one.
|